Melasma (Chlosma) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Melasma (Chlosma) - Pipeline Review, H1 2016', provides an overview of the Melasma (Chlosma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Melasma (Chlosma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Melasma (Chlosma) - The report reviews pipeline therapeutics for Melasma (Chlosma) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Melasma (Chlosma) therapeutics and enlists all their major and minor projects - The report assesses Melasma (Chlosma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Melasma (Chlosma) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Melasma (Chlosma) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Melasma (Chlosma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Melasma (Chlosma) Overview 7 Therapeutics Development 8 Pipeline Products for Melasma (Chlosma) - Overview 8 Melasma (Chlosma) - Therapeutics under Development by Companies 9 Melasma (Chlosma) - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Melasma (Chlosma) - Products under Development by Companies 12 Melasma (Chlosma) - Companies Involved in Therapeutics Development 13 EpiPharm AG 13 Hyundai Pharmaceutical Co., Ltd. 14 RXi Pharmaceuticals Corporation 15 Melasma (Chlosma) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Drug Profiles 24 EPI-M13 - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 HTB-003 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NPH-29 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 TRY-26071 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 TRY-26077 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Melasma (Chlosma) - Recent Pipeline Updates 29 Melasma (Chlosma) - Dormant Projects 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Number of Products under Development for Melasma (Chlosma), H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Melasma (Chlosma) - Pipeline by EpiPharm AG, H1 2016 13 Melasma (Chlosma) - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 14 Melasma (Chlosma) - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Melasma (Chlosma) Therapeutics - Recent Pipeline Updates, H1 2016 29 Melasma (Chlosma) - Dormant Projects, H1 2016 30
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.